<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="editorial"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cardiovasc Med</journal-id><journal-id journal-id-type="iso-abbrev">Front Cardiovasc Med</journal-id><journal-id journal-id-type="publisher-id">Front. Cardiovasc. Med.</journal-id><journal-title-group><journal-title>Frontiers in Cardiovascular Medicine</journal-title></journal-title-group><issn pub-type="epub">2297-055X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38116538</article-id><article-id pub-id-type="pmc">PMC10728870</article-id><article-id pub-id-type="doi">10.3389/fcvm.2023.1341650</article-id><article-categories><subj-group subj-group-type="heading"><subject>Cardiovascular Medicine</subject><subj-group><subject>Editorial</subject></subj-group></subj-group></article-categories><title-group><article-title>Editorial: Year in review: discussions in general cardiovascular medicine</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Accioli</surname><given-names>Riccardo</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1770462/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Salvini</surname><given-names>Viola</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1767900/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Xiao</surname><given-names>Junjie</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/53244/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Lazzerini</surname><given-names>Pietro Enea</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/158877/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Roever</surname><given-names>Leonardo</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/92819/overview"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Acampa</surname><given-names>Maurizio</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref><uri xlink:href="https://loop.frontiersin.org/people/377516/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1"><label><sup>1</sup></label><institution>Department of Medical Sciences, Surgery and Neurosciences, University of Siena</institution>, <addr-line>Siena</addr-line>, <country>Italy</country></aff><aff id="aff2"><label><sup>2</sup></label><institution>Institute of Cardiovascular Sciences, Shanghai Engineering Research Center of Organ Repair, School of Life Science, Shanghai University</institution>, <addr-line>Shanghai</addr-line>, <country>China</country></aff><aff id="aff3"><label><sup>3</sup></label><institution>Department of Clinical Research, Brazilian Evidence-Based Health Network</institution>, <addr-line>Uberl&#x000e2;ndia</addr-line>, <country>Brazil</country></aff><aff id="aff4"><label><sup>4</sup></label><institution>Gilbert and Rose -Marie Chagoury School of Medicine, Lebanese American University</institution>, <addr-line>Beirut</addr-line>, <country>Lebanon</country></aff><author-notes><fn fn-type="edited-by"><p><bold>Edited and Reviewed by:</bold> Coen van Solingen, New York University, United States</p></fn><fn fn-type="edited-by"><p><bold>Reviewed by:</bold> Xiu Liu, Southern Medical University, China</p></fn><corresp id="cor1"><label>*</label><bold>Correspondence:</bold> Maurizio Acampa <email>m.acampa@ao-siena.toscana.it</email></corresp></author-notes><pub-date pub-type="epub"><day>05</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>10</volume><elocation-id>1341650</elocation-id><history><date date-type="received"><day>20</day><month>11</month><year>2023</year></date><date date-type="accepted"><day>23</day><month>11</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; 2023 Accioli, Salvini, Xiao, Lazzerini, Roever and Acampa.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Accioli, Salvini, Xiao, Lazzerini, Roever and Acampa</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><kwd-group><kwd>coronary artery disease</kwd><kwd>cardiac hypertrophy</kwd><kwd>abdominal aortic disease</kwd><kwd>inflammation</kwd><kwd>cardiovascular medicine</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.</funding-source></award-group><funding-statement>The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.</funding-statement></funding-group><counts><fig-count count="0"/><table-count count="0"/><equation-count count="0"/><ref-count count="29"/><page-count count="0"/><word-count count="0"/></counts><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>General Cardiovascular Medicine</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p><bold>Editorial on the Research Topic</bold>
<ext-link xlink:href="https://www.frontiersin.org/research-topics/44671/year-in-review-discussions-in-general-cardiovascular-medicine" ext-link-type="uri">Year in review: discussions in general cardiovascular medicine</ext-link></p><p>This Research Topic sought to ignite meaningful discussions and enhance our understanding of the advancements and perspectives presented in selected articles from the field of Cardiovascular Medicine in 2022. These articles garnered notable attention throughout the year especially addressing various topics, including coronary artery disease (CAD), cardiac hypertrophy and abdominal aortic disease (AAA).</p><p>The mortality rate associated with CAD has declined over recent decades; however, it remains a leading cause of death worldwide, imposing a significant economic burden (<xref rid="B1" ref-type="bibr">1</xref>). One of the most important aspects in this setting is represented by refractory angina pectoris, a clinical condition characterized by persistent symptoms lasting beyond 3 months, even with the escalation of pharmacotherapy, including second- and third-line pharmacological agents, as well as bypass grafting, stenting, or percutaneous coronary intervention (PCI) of chronic total coronary occlusion (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>). Since the number of subjects with CAD who develop refractory angina pectoris despite optimal medical treatment including exercised based cardiac rehabilitation is growing (<xref rid="B4" ref-type="bibr">4</xref>&#x02013;<xref rid="B6" ref-type="bibr">6</xref>), it is of great scientific interest to discover new therapeutic strategies in this field. To better comprehend these aspects, <ext-link xlink:href="https://doi.org/10.3389/fcvm.2023.1228201" ext-link-type="uri">Chen et al.</ext-link> conducted a 20-year (2003&#x02013;2022) bibliometric analysis, highlighting the potential role of novel treatment methods, including spinal cord stimulation, enhanced external counterpulsation, stem cell therapy, and the coronary sinus reducer. However, despite these advancements, the absence of high-quality randomized controlled trials, long-term evidence of benefits, and cost-effectiveness studies limits their use in refractory angina pectoris. For these reasons, the authors emphasize the need for further research to better understand their potential impact on refractory angina outcome, and, more generally, on CAD outcome.</p><p>In this regard, it is worth highlighting how a significative portion of cases of CAD, up to 15%, is due to nonobstructive coronary artery myocardial infarction (MINOCA), defined as myocardial infarction in presence of coronary artery stenosis &#x0003c;50% at angiography (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>). The absence of significant coronary stenosis highlights the role of non-atherosclerotic thrombogenic mechanisms, in which the use of antiplatelet therapy may not be efficacious, given the unclear relationship between certain etiologies and platelet function that could negatively impact the final outcome (<xref rid="B9" ref-type="bibr">9</xref>). On this important topic, <ext-link xlink:href="https://doi.org/10.3389/fcvm.2022.1081934" ext-link-type="uri">Chen et al.</ext-link> provide an important viewpoint regarding principal aspects of this phenomenon, including a discussion of the types of MINOCA antiplatelet drugs, possible etiologies, and interesting clinical perspectives about MINOCA guidelines and clinical studies. In particular, the authors show the lack of convincing evidence to demonstrate the beneficial effect of dual antiplatelet therapy in the presence of small plaque rupture in non-significant stenosis and non-thrombotic coverage. The absence of a clear indication for antiplatelets on one side suggests the importance of conducting appropriate study populations and prospective randomized controlled trials to better evaluate the impact of antiplatelets agents; on the other hand, it strengthens the use of statins and angiotensin-converting enzyme inhibitor/angiotensin II receptor antagonist, now the only drugs able to reduce mortality in MINOCA patients. Lastly, the authors emphasize the importance of comprehending the underlying cause. This last point is crucial in antiplatelet responsiveness, especially when platelets are not involved in the phenomenon genesis (<xref rid="B10" ref-type="bibr">10</xref>). An important contribution to this non-thrombotic state is given to the discrepancy between oxygen demand/offer, for example during cardiac hypertrophy. In this scenario, the role of systemic inflammation in cardiovascular diseases is increasingly well-known. Cardiac hypertrophy, characterized by an increase in cardiomyocyte size (<xref rid="B11" ref-type="bibr">11</xref>), is a physiological adaptive response to various stimuli, such as exercise and pregnancy (<xref rid="B12" ref-type="bibr">12</xref>). Nevertheless, it can also be caused by pathological factors, such as increased interstitial fibrosis, cell death, cardiac dysfunction and the release of proinflammatory cytokines (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>). An important view about this phenomenon is reported by <ext-link xlink:href="https://doi.org/10.3389/fcvm.2023.1143583" ext-link-type="uri">Zhang et al.</ext-link> In their review, the authors describe the role of toll-like receptors (TLRs), innate immune response receptors, as a key factor in cardiovascular diseases. TLRs are a family of pattern recognition receptors that can identify pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). TLRs interact with their ligands and co-receptors to induce the expression of numerous inflammatory factors and inflammatory cell infiltration into the heart, leading to cardiac hypertrophy and heart failure through various inflammatory pathways (<ext-link xlink:href="https://doi.org/10.3389/fcvm.2023.1143583" ext-link-type="uri">Zhang et al.</ext-link>). The TLRs more closely related to cardiac hypertrophy are TLR2, TLR3, TLR4, TLR5, TLR7/8 and TLR9. Currently, there is little evidence in the literature on the role of TLR7/8 and TLR9 in cardiac hypertrophy, in particular on how they mediate inflammatory pathways and heart disease. Importantly, excessive activation of TLRs can lead to chronic inflammation and autoimmune diseases (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>). Future perspectives could develop drugs and methods to balance TLRs signaling, considering molecular target therapy against TLRs. Some of the TLR-based agonist and antagonist agents have been shown to be effective in preclinical models and are now entering clinical trials (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>). Overall, the goal is to understand the mechanism of the TLRs-mediated inflammatory response in cardiac hypertrophy and to identify potential therapeutic targets through TLRs' downstream and upstream signaling pathways.</p><p>Lastly, inflammation could involve not only the heart but also the vessels. In this regard, an important condition that influences the outcome of general population is represented by aortic disease. Abdominal aortic aneurysm (AAA) is an inflammatory vascular disease with associated high disability and mortality. Risk factors for the development of this disease are old age, high blood pressure, male sex, aortic atherosclerosis and smoking (<xref rid="B19" ref-type="bibr">19</xref>&#x02013;<xref rid="B22" ref-type="bibr">22</xref>). Thanks to the improvement of screening techniques, the incidence of AAA increases annually. The progression and pathophysiology of AAA are characterized by inflammatory destruction. As seen in the review by <ext-link xlink:href="https://doi.org/10.3389/fcvm.2022.1063683" ext-link-type="uri">Ling et al.</ext-link> the gut microbiota, an &#x0201c;invisible organ&#x0201d;, can contribute to the formation and progression of AAA by directly or indirectly promoting the inflammation of the vascular wall via release of intestinal metabolites, in turn activating TLRs and cell-mediated immunity (<xref rid="B23" ref-type="bibr">23</xref>), responsible for intensified arterial wall remodelling (<xref rid="B24" ref-type="bibr">24</xref>). The imbalance between pathological and symbiotic bacteria in the gut can lead to changes in immune development and inappropriate inflammatory responses, but it is not yet known whether this imbalance is the cause or result of AAA (<ext-link xlink:href="https://doi.org/10.3389/fcvm.2022.1063683" ext-link-type="uri">Ling et al.</ext-link>). Gut probiotics, antibiotics, immune modulators, nitric oxide, cholesterol-lowering drugs, gut microbiota transplantation, through the modulation of the vascular inflammatory response, could represent new therapeutic perspectives for AAA (<xref rid="B25" ref-type="bibr">25</xref>&#x02013;<xref rid="B29" ref-type="bibr">29</xref>).</p><p>In conclusion, this Research Topic has not only facilitated insightful discussions but has also enriched our comprehension of pivotal developments and perspectives in Cardiovascular Medicine during 2022. While highlighting emerging therapeutic strategies, these articles emphasize the imperative for further research, to provide continued advancements in understanding, diagnosis, and treatment strategies, ultimately contributing to improved patient outcomes.</p></body><back><sec sec-type="author-contributions" id="s1"><title>Author contributions</title><p>RA: Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. VS: Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. JX: Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. PL: Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. LR: Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. MA: Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="s3"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p><p>The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p></sec><sec sec-type="disclaimer" id="s4"><title>Publisher's note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duggan</surname><given-names>JP</given-names></name><name><surname>Peters</surname><given-names>AS</given-names></name><name><surname>Trachiotis</surname><given-names>GD</given-names></name><name><surname>Antevil</surname><given-names>JL</given-names></name></person-group>. <article-title>Epidemiology of coronary artery disease</article-title>. <source>Surg Clin North Am</source><italic>.</italic> (<year>2022</year>) <volume>102</volume>(<issue>3</issue>):<fpage>499</fpage>&#x02013;<lpage>516</lpage>. <pub-id pub-id-type="doi">10.1016/j.suc.2022.01.007</pub-id><pub-id pub-id-type="pmid">35671770</pub-id>
</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montalescot</surname><given-names>G</given-names></name><name><surname>Sechtem</surname><given-names>U</given-names></name><name><surname>Achenbach</surname><given-names>S</given-names></name><name><surname>Andreotti</surname><given-names>F</given-names></name><name><surname>Arden</surname><given-names>C</given-names></name><name><surname>Budaj</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European society of cardiology</article-title>. <source>Eur Heart J</source><italic>.</italic> (<year>2013</year>) <volume>34</volume>(<issue>38</issue>):<fpage>2949</fpage>&#x02013;<lpage>3003</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/eht296</pub-id><pub-id pub-id-type="pmid">23996286</pub-id>
</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mannheimer</surname><given-names>C</given-names></name><name><surname>Camici</surname><given-names>P</given-names></name><name><surname>Chester</surname><given-names>MR</given-names></name><name><surname>Collins</surname><given-names>A</given-names></name><name><surname>DeJongste</surname><given-names>M</given-names></name><name><surname>Eliasson</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>The problem of chronic refractory angina; report from the ESC joint study group on the treatment of refractory angina</article-title>. <source>Eur Heart J</source><italic>.</italic> (<year>2002</year>) <volume>23</volume>(<issue>5</issue>):<fpage>355</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1053/euhj.2001.2706</pub-id><pub-id pub-id-type="pmid">11846493</pub-id>
</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vervaat</surname><given-names>FE</given-names></name><name><surname>van der Gaag</surname><given-names>A</given-names></name><name><surname>Teeuwen</surname><given-names>K</given-names></name><name><surname>van Suijlekom</surname><given-names>H</given-names></name><name><surname>Wijnbergen</surname><given-names>I</given-names></name></person-group>. <article-title>Neuromodulation in patients with refractory angina pectoris: a review</article-title>. <source>Eur Heart J Open</source><italic>.</italic> (<year>2023</year>) <volume>3</volume>(<issue>1</issue>):<fpage>oeac083</fpage>. <pub-id pub-id-type="doi">10.1093/ehjopen/oeac083</pub-id><pub-id pub-id-type="pmid">36632476</pub-id>
</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Spanos</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Lu</surname><given-names>R</given-names></name><name><surname>Bei</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Exercise training maintains cardiovascular health: signaling pathways involved and potential therapeutics</article-title>. <source>Signal Transduct Target Ther</source><italic>.</italic> (<year>2022</year>) <volume>7</volume>(<issue>1</issue>):<fpage>306</fpage>. <pub-id pub-id-type="doi">10.1038/s41392-022-01153-1</pub-id><pub-id pub-id-type="pmid">36050310</pub-id>
</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Rosenzweig</surname><given-names>AJ</given-names></name></person-group>. <article-title>Exercise and cardiovascular protection: update and future</article-title>. <source>Sport Health Sci</source>. (<year>2021</year>) <volume>10</volume>(<issue>6</issue>):<fpage>607</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.jshs.2021.11.001</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdu</surname><given-names>FA</given-names></name><name><surname>Mohammed</surname><given-names>AQ</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Che</surname><given-names>W</given-names></name></person-group>. <article-title>Myocardial infarction with nonobstructive coronary arteries (MINOCA): a review of the current position</article-title>. <source>Cardiology</source><italic>.</italic> (<year>2020</year>) <volume>145</volume>(<issue>9</issue>):<fpage>543</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1159/000509100</pub-id><pub-id pub-id-type="pmid">32750696</pub-id>
</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trisha</surname><given-names>S</given-names></name><name><surname>Andrew</surname><given-names>RC</given-names></name><name><surname>Marc</surname><given-names>RD</given-names></name><name><surname>Nicholas</surname><given-names>LM</given-names></name><name><surname>David</surname><given-names>EN</given-names></name></person-group>. <article-title>MINOCA: a heterogenous group of conditions associated with myocardial damage</article-title>. <source>Heart</source><italic>.</italic> (<year>2021</year>) <volume>107</volume>(<issue>18</issue>):<fpage>1458</fpage>. <pub-id pub-id-type="doi">10.1136/heartjnl-2020-318269</pub-id><pub-id pub-id-type="pmid">33568434</pub-id>
</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valgimigli</surname><given-names>M</given-names></name><name><surname>Bueno</surname><given-names>H</given-names></name><name><surname>Byrne</surname><given-names>RA</given-names></name><name><surname>Collet</surname><given-names>HP</given-names></name><name><surname>Costa</surname><given-names>F</given-names></name><name><surname>Jeppsson</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European society of cardiology (ESC) and of the European association for cardio-thoracic surgery (EACTS)</article-title>. <source>Eur Heart J</source><italic>.</italic> (<year>2018</year>) <volume>39</volume>(<issue>3</issue>):<fpage>213</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehx419</pub-id><pub-id pub-id-type="pmid">28886622</pub-id>
</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindahl</surname><given-names>B</given-names></name><name><surname>Baron</surname><given-names>T</given-names></name><name><surname>Albertucci</surname><given-names>M</given-names></name><name><surname>Prati</surname><given-names>F</given-names></name></person-group>. <article-title>Myocardial infarction with non-obstructive coronary artery disease</article-title>. <source>EuroIntervention</source><italic>.</italic> (<year>2021</year>) <volume>17</volume>(<issue>11</issue>):<fpage>e875</fpage>&#x02013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.4244/eij-d-21-00426</pub-id><pub-id pub-id-type="pmid">34870600</pub-id>
</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oldfield</surname><given-names>CJ</given-names></name><name><surname>Duhamel</surname><given-names>TA</given-names></name><name><surname>Dhalla</surname><given-names>NS</given-names></name></person-group>. <article-title>Mechanisms for the transition from physiological to pathological cardiac hypertrophy</article-title>. <source>Can J Physiol Pharmacol</source><italic>.</italic> (<year>2020</year>) <volume>98</volume>(<issue>2</issue>):<fpage>74</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1139/cjpp-2019-0566</pub-id><pub-id pub-id-type="pmid">31815523</pub-id>
</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name></person-group>. <article-title>Non-coding RNAs in physiological cardiac hypertrophy</article-title>. <source>Adv Exp Med Biol</source><italic>.</italic> (<year>2020</year>) <volume>1229</volume>:<fpage>149</fpage>&#x02013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1007/978-981-15-1671-9_8</pub-id><pub-id pub-id-type="pmid">32285410</pub-id>
</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samak</surname><given-names>M</given-names></name><name><surname>Fatullayev</surname><given-names>J</given-names></name><name><surname>Sabashnikov</surname><given-names>A</given-names></name><name><surname>Zeriouh</surname><given-names>M</given-names></name><name><surname>Schmack</surname><given-names>B</given-names></name><name><surname>Faraget</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Cardiac hypertrophy: an Introduction to molecular and cellular basis</article-title>. <source>Med Sci Monit Basic Res</source><italic>.</italic> (<year>2016</year>) <volume>22</volume>:<fpage>75</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.12659/msmbr.900437</pub-id><pub-id pub-id-type="pmid">27450399</pub-id>
</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernardo</surname><given-names>BC</given-names></name><name><surname>Weeks</surname><given-names>KL</given-names></name><name><surname>Pretorius</surname><given-names>L</given-names></name><name><surname>McMullen</surname><given-names>JR</given-names></name></person-group>. <article-title>Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies</article-title>. <source>Pharmacol Ther</source><italic>.</italic> (<year>2010</year>) <volume>128</volume>(<issue>1</issue>):<fpage>191</fpage>&#x02013;<lpage>227</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2010.04.005</pub-id><pub-id pub-id-type="pmid">20438756</pub-id>
</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soraci</surname><given-names>L</given-names></name><name><surname>Gambuzza</surname><given-names>ME</given-names></name><name><surname>Biscetti</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Toll-like receptors and NLRP3 inflammasome-dependent pathways in Parkinson&#x02019;s disease: mechanisms and therapeutic implications</article-title>. <source>J Neurol</source><italic>.</italic> (<year>2023</year>) <volume>270</volume>(<issue>3</issue>):<fpage>1346</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1007/s00415-022-11491-3</pub-id><pub-id pub-id-type="pmid">36460875</pub-id>
</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bezhaeva</surname><given-names>T</given-names></name><name><surname>Karper</surname><given-names>J</given-names></name><name><surname>Quax</surname><given-names>PHA</given-names></name><name><surname>de Vries</surname><given-names>MR</given-names></name></person-group>. <article-title>The intriguing role of TLR accessory molecules in cardiovascular health and disease</article-title>. <source>Front Cardiovasc Med</source><italic>.</italic> (<year>2022</year>) <volume>9</volume>:<fpage>820962</fpage>. <pub-id pub-id-type="doi">10.3389/fcvm.2022.820962</pub-id><pub-id pub-id-type="pmid">35237675</pub-id>
</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anwar</surname><given-names>MA</given-names></name><name><surname>Shah</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name></person-group>. <article-title>Recent clinical trends in toll-like receptor targeting therapeutics</article-title>. <source>Med Res Rev</source><italic>.</italic> (<year>2019</year>) <volume>39</volume>(<issue>3</issue>):<fpage>1053</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1002/med.21553</pub-id><pub-id pub-id-type="pmid">30450666</pub-id>
</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farooq</surname><given-names>M</given-names></name><name><surname>Batool</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>MS</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name></person-group>. <article-title>Toll-Like receptors as a therapeutic target in the era of immunotherapies</article-title>. <source>Front Cell Dev Biol</source><italic>.</italic> (<year>2021</year>) <volume>9</volume>:<fpage>756315</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2021.756315</pub-id><pub-id pub-id-type="pmid">34671606</pub-id>
</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>L</given-names></name><name><surname>Folsom</surname><given-names>AR</given-names></name><name><surname>Alonso</surname><given-names>A</given-names></name><name><surname>Lutsey</surname><given-names>PL</given-names></name><name><surname>Pankow</surname><given-names>JS</given-names></name><name><surname>Guan</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>Association of carotid atherosclerosis and stiffness with abdominal aortic aneurysm: the atherosclerosis risk in communities (ARIC) study</article-title>. <source>Atherosclerosis</source><italic>.</italic> (<year>2018</year>) <volume>270</volume>:<fpage>110</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2018.01.044</pub-id><pub-id pub-id-type="pmid">29407878</pub-id>
</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsao</surname><given-names>CW</given-names></name><name><surname>Aday</surname><given-names>AW</given-names></name><name><surname>Almarzooq</surname><given-names>ZI</given-names></name><name><surname>Alonso</surname><given-names>A</given-names></name><name><surname>Beaton</surname><given-names>AZ</given-names></name><name><surname>Bittencourt</surname><given-names>MS</given-names></name><etal/></person-group>
<article-title>Heart disease and stroke statistics-2022 update: a report from the American heart association</article-title>. <source>Circulation</source><italic>.</italic> (<year>2022</year>) <volume>145</volume>(<issue>8</issue>):<fpage>e153</fpage>&#x02013;<lpage>639</lpage>. <pub-id pub-id-type="doi">10.1161/cir.0000000000001052</pub-id><pub-id pub-id-type="pmid">35078371</pub-id>
</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Yao</surname><given-names>L</given-names></name><name><surname>Roetker</surname><given-names>NS</given-names></name><name><surname>Alonso</surname><given-names>A</given-names></name><name><surname>Lutsey</surname><given-names>PL</given-names></name><name><surname>Steenson</surname><given-names>CC</given-names></name><etal/></person-group>
<article-title>Lifetime risk and risk factors for abdominal aortic aneurysm in a 24-year prospective study: the ARIC study (atherosclerosis risk in communities)</article-title>. <source>Arterioscler Thromb Vasc Biol</source><italic>.</italic> (<year>2016</year>) <volume>36</volume>(<issue>12</issue>):<fpage>2468</fpage>&#x02013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1161/atvbaha.116.308147</pub-id><pub-id pub-id-type="pmid">27834688</pub-id>
</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>HA</given-names></name><name><surname>Cicalese</surname><given-names>S</given-names></name><name><surname>Preston</surname><given-names>KJ</given-names></name><name><surname>Kawai</surname><given-names>T</given-names></name><name><surname>Okuno</surname><given-names>K</given-names></name><name><surname>Choi</surname><given-names>ET</given-names></name><etal/></person-group>
<article-title>Targeting mitochondrial fission as a potential therapeutic for abdominal aortic aneurysm</article-title>. <source>Cardiovasc Res</source><italic>.</italic> (<year>2021</year>) <volume>117</volume>(<issue>3</issue>):<fpage>971</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1093/cvr/cvaa133</pub-id><pub-id pub-id-type="pmid">32384150</pub-id>
</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>N</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Jiao</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>A unique population of regulatory T cells in heart potentiates cardiac protection from myocardial infarction</article-title>. <source>Circulation</source><italic>.</italic> (<year>2020</year>) <volume>142</volume>(<issue>20</issue>):<fpage>1956</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.046789</pub-id><pub-id pub-id-type="pmid">32985264</pub-id>
</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jab&#x00142;o&#x00144;ska</surname><given-names>A</given-names></name><name><surname>Neumayer</surname><given-names>C</given-names></name><name><surname>Bolliger</surname><given-names>M</given-names></name><name><surname>Gollackner</surname><given-names>B</given-names></name><name><surname>Klinger</surname><given-names>M</given-names></name><name><surname>Paradowska</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Analysis of host toll-like receptor 3 and RIG-I-like receptor gene expression in patients with abdominal aortic aneurysm</article-title>. <source>J Vasc Surg</source><italic>.</italic> (<year>2018</year>) <volume>68</volume>(<issue>6s</issue>):<fpage>39s</fpage>&#x02013;<lpage>46s</lpage>. <pub-id pub-id-type="doi">10.1016/j.jvs.2017.10.087</pub-id><pub-id pub-id-type="pmid">29567028</pub-id>
</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadav</surname><given-names>MK</given-names></name><name><surname>Kumari</surname><given-names>I</given-names></name><name><surname>Singh</surname><given-names>B</given-names></name><name><surname>Sharma</surname><given-names>KK</given-names></name><name><surname>Tiwari</surname><given-names>SK</given-names></name></person-group>. <article-title>Probiotics, prebiotics and synbiotics: safe options for next-generation therapeutics</article-title>. <source>Appl Microbiol Biotechnol</source><italic>.</italic> (<year>2022</year>) <volume>106</volume>(<issue>2</issue>):<fpage>505</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1007/s00253-021-11646-8</pub-id><pub-id pub-id-type="pmid">35015145</pub-id>
</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shikata</surname><given-names>F</given-names></name><name><surname>Shimada</surname><given-names>K</given-names></name><name><surname>Sato</surname><given-names>H</given-names></name><name><surname>Ikedo</surname><given-names>T</given-names></name><name><surname>Kuwabara</surname><given-names>A</given-names></name><name><surname>Furukawa</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Potential influences of gut microbiota on the formation of intracranial aneurysm</article-title>. <source>Hypertension</source><italic>.</italic> (<year>2019</year>) <volume>73</volume>(<issue>2</issue>):<fpage>491</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1161/hypertensionaha.118.11804</pub-id><pub-id pub-id-type="pmid">30624992</pub-id>
</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umebayashi</surname><given-names>R</given-names></name><name><surname>Uchida</surname><given-names>HA</given-names></name><name><surname>Kakio</surname><given-names>Y</given-names></name><name><surname>Subramanian</surname><given-names>V</given-names></name><name><surname>Daugherty</surname><given-names>A</given-names></name><name><surname>Wada</surname><given-names>J</given-names></name></person-group>. <article-title>Cilostazol attenuates angiotensin II-induced abdominal aortic aneurysms but not atherosclerosis in apolipoprotein E-deficient mice</article-title>. <source>Arterioscler Thromb Vasc Biol</source><italic>.</italic> (<year>2018</year>) <volume>38</volume>(<issue>4</issue>):<fpage>903</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1161/atvbaha.117.309707</pub-id><pub-id pub-id-type="pmid">29437572</pub-id>
</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poorsattar Bejeh-Mir</surname><given-names>A</given-names></name><name><surname>Parsian</surname><given-names>H</given-names></name><name><surname>Akbari Khoram</surname><given-names>M</given-names></name><name><surname>Ghasemi</surname><given-names>N</given-names></name><name><surname>Bijani</surname><given-names>A</given-names></name><name><surname>Khosravi-Samani</surname><given-names>M</given-names></name></person-group>. <article-title>Diagnostic role of salivary and GCF nitrite, nitrate and nitric oxide to distinguish healthy periodontium from gingivitis and periodontitis</article-title>. <source>Int J Mol Cell Med</source><italic>.</italic> (<year>2014</year>) <volume>3</volume>(<issue>3</issue>):<fpage>138</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">25317400</pub-id>
</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>RP</given-names></name><name><surname>Hopkins</surname><given-names>R</given-names></name><name><surname>Eaton</surname><given-names>TE</given-names></name></person-group>. <article-title>Pharmacological actions of statins: potential utility in COPD</article-title>. <source>Eur Respir Rev</source><italic>.</italic> (<year>2009</year>) <volume>18</volume>(<issue>114</issue>):<fpage>222</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1183/09059180.00005309</pub-id><pub-id pub-id-type="pmid">20956147</pub-id>
</mixed-citation></ref></ref-list></back></article>
